Effect of Virulence Factors on the Photodynamic Inactivation of Cryptococcus neoformans

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Prates, Renato A ^a,b,c,d   Fuchs, Beth Burgwyn ^c   Mizuno, Kazue ^c,d   Naqvi, Qurat ^c   Kato, Ilka T ^a   Ribeiro, Martha S ^a   Mylonakis, Eleftherios ^c   Tegos, George P ^c,d,e   Hamblin, Michael R ^c,d,f  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b UNIVERSIDADE NOVE DE JULHO   (Brazil)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACCASE; METHYLENE BLUE; PHOTOSENSITIZING AGENT; ROSE BENGAL; SELENIUM;

APOPTOSIS; ARTICLE; CELL VIABILITY; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DESENSITIZATION; DOSIMETRY; FUNGAL STRAIN; FUNGAL VIRULENCE; ILLUMINATION; LASER MICROSCOPY; NONHUMAN; PHENOTYPE; PHOTODYNAMIC INACTIVATION; PHOTODYNAMICS;

ANTIFUNGAL AGENTS; CELL WALL; COINFECTION; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HIV; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LIGHT; PHOTOSENSITIZING AGENTS; REACTIVE OXYGEN SPECIES;

FILOBASIDIELLA NEOFORMANS;

EID: 84872546513     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054387     Document Type: Article

References (68)

1. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, et al. (2001) Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33: 641-647.
2. Espinel-Ingroff A, (2009) Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol 26: 15-22.
3. Zaragoza O, McClelland EE, Telzak A, Casadevall A, (2006) Equatorial ring-like channels in the Cryptococcus neoformans polysaccharide capsule. FEMS Yeast Res 6: 662-666.
4. Casadevall A, Cleare W, Feldmesser M, Glatman-Freedman A, Goldman DL, et al. (1998) Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother 42: 1437-1446.
5. Casadevall A, Perfect JR (1998) Cryptococcus neoformans; Microbiology ASf, editor. Washington: ASM Press. 549 p.
6. Vecchiarelli A, (2000) Immunoregulation by capsular components of Cryptococcus neoformans. Med Mycol 38: 407-417.
7. Silva EG, Baroni Fde A, Viani FC, Ruiz Lda S, Gandra RF, et al. (2006) Virulence profile of strains of Cryptococcus neoformans var. grubii evaluated by experimental infection in BALB/c mice and correlation with exoenzyme activity. J Med Microbiol 55: 139-142.
8. Garber G, (2001) An overview of fungal infections. Drugs 61Suppl 1: 1-12.
9. Sorrell TC, (2001) Cryptococcus neoformans variety gattii. Med Mycol 39: 155-168.
10. Seaton RA, Naraqi S, Wembri JP, Warrell DA, (1997) Cell-mediated immunity in HIV seronegative patients recovered from Cryptococcus neoformans var. gattii meningitis. J Med Vet Mycol 35: 7-11.
11. Hay RJ (1991) Overview of the treatment of disseminated fungal infections. J Antimicrob Chemother 28 Suppl B: 17-25.
12. Chang YC, Kwon-Chung KJ, (1999) Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans. J Bacteriol 181: 5636-5643.
13. Casadevall A, Mukherjee J, Yuan R, Perfect J, (1994) Management of injuries caused by Cryptococcus neoformans-contaminated needles. Clin Infect Dis 19: 951-953.
14. Steinbach WJ, Benjamin DK, (2005) New antifungal agents under development in children and neonates. Curr Opin Infect Dis 18: 484-489.
15. Sanglard D, Odds FC, (2002) Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2: 73-85.
16. Fuchs BB, Tegos GP, Hamblin MR, Mylonakis E, (2007) Susceptibility of Cryptococcus neoformans to photodynamic inactivation is associated with cell wall integrity. Antimicrob Agents Chemother 51: 2929-2936.
17. Rodrigues GB, Primo FL, Tedesco AC, Braga GU, (2012) In vitro photodynamic inactivation of Cryptococcus neoformans melanized cells with chloroaluminum phthalocyanine nanoemulsion. Photochem Photobiol 88: 440-447.
18. Dai T, Fuchs BB, Coleman JJ, Prates RA, Astrakas C, et al. (2012) Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. Front Microbiol 3: 120.
19. Soares B, Alves O, Ferreira M, Amorim J, Sousa G, et al. (2011) Cryptococcus gattii: in vitro susceptibility to photodynamic inactivation. Photochem Photobiol 87: 357-364.
20. Dai TH, Tegos GP, Zhiyentayev T, Mylonakis E, Hamblin MR, (2010) Photodynamic Therapy for Methicillin-Resistant Staphylococcus aureus Infection in a Mouse Skin Abrasion Model. Lasers Surg Med 42: 38-44.
21. Dai T, Huang YY, Hamblin MR, (2009) Photodynamic therapy for localized infections-State of the art. Photodiagnosis Photodyn Ther 6: 170-188.
22. Prates RA, da Silva EG, Yamada AM, Suzuki LC, Paula CR, et al. (2009) Light parameters influence cell viability in antifungal photodynamic therapy in a fluence and rate fluence-dependent manner. Laser Phys 19: 1038-1044.
23. Moan J, Peng Q, (2003) An outline of the hundred-year history of PDT. Anticancer Res 23: 3591-3600.
24. Dolmans DE, Fukumura D, Jain RK, (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3: 380-387.
25. Cruess AF, Zlateva G, Pleil AM, Wirostko B, (2009) Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol 87: 118-132.
26. Hamblin MR, Hasan T, (2004) Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci 3: 436-450.
27. Jori G, Fabris C, Soncin M, Ferro S, Coppellotti O, et al. (2006) Photodynamic therapy in the treatment of microbial infections: Basic principles and perspective applications. Lasers Surg Med 38: 468-481.
28. Wainwright M, (1998) Photodynamic antimicrobial chemotherapy (PACT). J Antimicrob Chemother 42: 13-28.
29. Demidova TN, Hamblin MR, (2004) Photodynamic therapy targeted to pathogens. Int J Immunopathol Pharmacol 17: 245-254.
30. Prates RA, Yamada-Jr AM, Suzuki LC, Eiko Hashimoto MC, Cai S, et al. (2007) Bactericidal effect of malachite green and red laser on Actinobacillus actinomycetemcomitans. J Photochem Photobiol B 86: 70-76.
31. Konan YN, Gurny R, Allemann E, (2002) State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B 66: 89-106.
32. Wainwright M, Byrne MN, Gattrell MA, (2006) Phenothiazinium-based photobactericidal materials. J Photochem Photobiol B 84: 227-230.
33. Castano A, Demidova TN, Hamblin MR, (2004) Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagn Photodynam Ther 1: 279-293.
34. Huang L, Huang YY, Mroz P, Tegos GP, Zhiyentayev T, et al. (2010) Stable synthetic cationic bacteriochlorins as selective antimicrobial photosensitizers. Antimicrob Agents Chemother 54: 3834-3841.
35. Schafer M, Schmitz C, Facius R, Horneck G, Milow B, et al. (2000) Systematic study of parameters influencing the action of Rose Bengal with visible light on bacterial cells: comparison between the biological effect and singlet-oxygen production. Photochem Photobiol 71: 514-523.
36. Harris F, Chatfield LK, Phoenix DA, (2005) Phenothiazinium based photosensitisers-photodynamic agents with a multiplicity of cellular targets and clinical applications. Curr Drug Targets 6: 615-627.
37. Foley JW, Song X, Demidova TN, Jalil F, Hamblin MR, (2006) Synthesis and properties of benzo[a]phenoxazinium chalcogen analogues as novel broad-spectrum antimicrobial photosensitizers. J Med Chem 49: 5291-5299.
38. Huang L, Terakawa M, Zhiyentayev T, Huang YY, Sawayama Y, et al. (2010) Innovative cationic fullerenes as broad-spectrum light-activated antimicrobials. Nanomedicine 6: 442-452.
39. Tegos GP, Demidova TN, Arcila-Lopez D, Lee H, Wharton T, et al. (2005) Cationic fullerenes are effective and selective antimicrobial photosensitizers. Chem Biol 12: 1127-1135.
40. Demidova TN, Hamblin MR, (2005) Effect of cell-photosensitizer binding and cell density on microbial photoinactivation. Antimicrob Agents Chemother 49: 2329-2335.
41. Prates RA, Kato IT, Ribeiro MS, Tegos GP, Hamblin MR, (2011) Influence of multidrug efflux systems on methylene blue-mediated photodynamic inactivation of Candida albicans. J Antimicrob Chemother 66: 1525-1532.
42. Wilson M, Yianni C, (1995) Killing of methicillin-resistant Staphylococcus aureus by low-power laser light. J Med Microbiol 42: 62-66.
43. Wilson M, (2004) Lethal photosensitisation of oral bacteria and its potential application in the photodynamic therapy of oral infections. Photochem Photobiol Sci 3: 412-418.
44. Monfrecola G, Procaccini EM, Bevilacqua M, Manco A, Calabro G, et al. (2004) In vitro effect of 5-aminolaevulinic acid plus visible light on Candida albicans. Photochem Photobiol Sci 3: 419-422.
45. Cowen LE, Anderson JB, Kohn LM, (2002) Evolution of drug resistance in Candida albicans. Annu Rev Microbiol 56: 139-165.
46. Mylonakis E, Idnurm A, Moreno R, El Khoury J, Rottman JB, et al. (2004) Cryptococcus neoformans Kin1 protein kinase homologue, identified through a Caenorhabditis elegans screen, promotes virulence in mammals. Mol Microbiol 54: 407-419.
47. Nelson RT, Hua J, Pryor B, Lodge JK, (2001) Identification of virulence mutants of the fungal pathogen Cryptococcus neoformans using signature-tagged mutagenesis. Genetics 157: 935-947.
48. Williamson PR, Wakamatsu K, Ito S, (1998) Melanin biosynthesis in Cryptococcus neoformans. J Bacteriol 180: 1570-1572.
49. Rosas AL, Casadevall A, (1997) Melanization affects susceptibility of Cryptococcus neoformans to heat and cold. FEMS Microbiol Lett 153: 265-272.
50. Hamblin MR, O'Donnell DA, Murthy N, Rajagopalan K, Michaud N, et al. (2002) Polycationic photosensitizer conjugates: effects of chain length and Gram classification on the photodynamic inactivation of bacteria. J Antimicrob Chemother 49: 941-951.
51. Jett BD, Hatter KL, Huycke MM, Gilmore MS, (1997) Simplified agar plate method for quantifying viable bacteria. Biotechniques 23: 648-650.
52. Pfaller MA, Burmeister L, Bartlett MS, Rinaldi MG, (1988) Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol 26: 1437-1441.
53. Zhu X, Gibbons J, Garcia-Rivera J, Casadevall A, Williamson PR, (2001) Laccase of Cryptococcus neoformans is a cell wall-associated virulence factor. Infect Immun 69: 5589-5596.
54. Wang Y, Casadevall A, (1994) Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect Immun 62: 3004-3007.
55. Khajo A, Bryan RA, Friedman M, Burger RM, Levitsky Y, et al. (2011) Protection of melanized Cryptococcus neoformans from lethal dose gamma irradiation involves changes in melanin's chemical structure and paramagnetism. PLoS One 6: e25092.
56. Garcia-Rivera J, Casadevall A, (2001) Melanization of Cryptococcus neoformans reduces its susceptibility to the antimicrobial effects of silver nitrate. Med Mycol 39: 353-357.
57. van Duin D, Casadevall A, Nosanchuk JD, (2002) Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother 46: 3394-3400.
58. Alanio A, Desnos-Ollivier M, Dromer F, (2011) Dynamics of Cryptococcus neoformans-macrophage interactions reveal that fungal background influences outcome during cryptococcal meningoencephalitis in humans. MBio 2: e00158-00111.
59. Fuchs B, O'Brien E, Khoury JB, Mylonakis E, (2010) Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence 1: 475-482.
60. Ostrosky-Zeichner L, Casadevall A, Galgiani J, Odds F, Rex J, (2010) An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 9: 719-727.
61. Ozaki K, Tanaka K, Imamura H, Hihara T, Kameyama T, et al. (1996) Rom1p and Rom2p are GDP/GTP exchange proteins (GEPs) for Rho1p small GTP binding proteins in Saccharomyces cerevisiae. EMBO J 15: 2196-2207.
62. Philip B, Levin D, (2001) Wsc1 and Mid2 are cell surface sensors for cell wall integrity signaling that act through Rom2, a guanine nucleotide exchange factor for Rho1. Mol Cell Biol 21: 271-280.
63. Mizuno K, Zhiyentayev T, Huang L, Khalil S, Nasim F, et al. (2011) Antimicrobial Photodynamic Therapy with Functionalized Fullerenes: Quantitative Structure-activity Relationships. J Nanomedic Nanotechnol 2: 109-117.
64. Huang L, Xuan Y, Koide Y, Zhiyentayev T, Tanaka M, et al. (2012) Type I and Type II mechanisms of antimicrobial photodynamic therapy: An in vitro study on gram-negative and gram-positive bacteria. Lasers Surg Med 44: 490-499.
65. Drakulic T, Temple MD, Guido R, Jarolim S, Breitenbach M, et al. (2005) Involvement of oxidative stress response genes in redox homeostasis, the level of reactive oxygen species, and ageing in Saccharomyces cerevisiae. FEMS Yeast Res 5: 1215-1228.
66. Li Q, McNeil B, Harvey LM, (2008) Adaptive response to oxidative stress in the filamentous fungus Aspergillus niger B1-D. Free Radic Biol Med 44: 394-402.
67. Lam M, Jou PC, Lattif AA, Lee Y, Malbasa CL, et al. (2011) Photodynamic therapy with Pc 4 induces apoptosis of Candida albicans. Photochem Photobiol 87: 904-909.
68. Salas SD, Bennett JE, Kwon-Chung KJ, Perfect JR, Williamson PR, (1996) Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med 184: 377-386.